Published in Kidney Int on March 01, 1984
Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci. Clin Microbiol Rev (1988) 5.13
Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis. Clin Microbiol Rev (1992) 1.87
Infections associated with indwelling devices: infections related to extravascular devices. Antimicrob Agents Chemother (1989) 1.64
Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int (2012) 1.28
Heterogeneity in opsonic requirements of Staphylococcus epidermidis: relative importance of surface hydrophobicity, capsules and slime. Immunology (1989) 0.94
Effect of dialysate fluids on phagocytosis and killing by normal neutrophils. J Clin Microbiol (1987) 0.93
Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages. Infect Immun (1985) 0.87
Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Antimicrob Agents Chemother (1999) 0.86
Hydrogen peroxide generation by polymorphonuclear leukocytes exposed to peritoneal dialysis effluent. Clin Diagn Lab Immunol (1996) 0.83
Primary and secondary granule release by polymorphonuclear leukocytes exposed to peritoneal dialysis effluent. Clin Diagn Lab Immunol (1994) 0.82
Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution. Pediatr Nephrol (1995) 0.79
Is peritoneal dialysis a good long term treatment? Br Med J (Clin Res Ed) (1985) 0.79
Opsonic activity of intravenous immunoglobulin preparations against Staphylococcus epidermidis. J Clin Pathol (1986) 0.77
The use of exchange-free periods alternating with daily exchanges of icodextrin in the initial treatment of peritoneal dialysis-associated peritonitis: a safety study. Perit Dial Int (2014) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet (2004) 4.39
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria. J Immunol Methods (1977) 3.89
Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect (2004) 3.69
An antibiotic policy to prevent emergence of resistant bacilli. Lancet (2000) 3.56
Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine (Baltimore) (1980) 3.42
Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun (1978) 3.23
Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leukocytes and monocytes. J Infect Dis (1977) 3.09
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol (1992) 2.92
The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest (1978) 2.83
Effect of protein A on staphylococcal opsonization. Infect Immun (1977) 2.79
Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin Microbiol (1997) 2.71
Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis (1995) 2.69
Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother (2007) 2.62
Bacterial adherence to fibronectin and endothelial cells: a possible mechanism for bacterial tissue tropism. J Lab Clin Med (1984) 2.52
Detection of PCR inhibitors in cervical specimens by using the AMPLICOR Chlamydia trachomatis assay. J Clin Microbiol (1996) 2.52
Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet (1992) 2.47
Rapid detection of methicillin resistance in Staphylococcus aureus isolates by the MRSA-screen latex agglutination test. J Clin Microbiol (1999) 2.40
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis (1999) 2.38
Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun (1993) 2.23
Cryptic peptidoglycan and the antiphagocytic effect of the Staphylococcus aureus capsule: model for the antiphagocytic effect of bacterial cell surface polymers. Infect Immun (1979) 2.17
Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 2.09
Extracellular matrix proteins (fibronectin, laminin, and type IV collagen) bind and aggregate bacteria. Am J Pathol (1985) 2.08
Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanism of resistance to phagocytosis. Infect Immun (1979) 2.07
Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol (1999) 2.04
Activation of complement by cell surface components of Staphylococcus aureus. Infect Immun (1978) 2.03
Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. J Clin Microbiol (1997) 2.02
Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J Immunol (1982) 2.02
Inhibition of alternative complement pathway opsonization by group A streptococcal M protein. J Infect Dis (1979) 1.97
Human fibronectin binding to staphylococcal surface protein and its relative inefficiency in promoting phagocytosis by human polymorphonuclear leukocytes, monocytes, and alveolar macrophages. Infect Immun (1981) 1.97
A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med (1996) 1.96
Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med (1990) 1.95
Improved detection of Candida albicans by PCR in blood of neutropenic mice with systemic candidiasis. J Clin Microbiol (1995) 1.93
Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV. Infect Immun (1977) 1.92
Detection of Chlamydia trachomatis in male and female urine specimens by using the amplified Chlamydia trachomatis test. J Clin Microbiol (1997) 1.91
Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun (1995) 1.91
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol (1998) 1.84
The glomerular mesangium. Kidney Int (1980) 1.83
Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections. J Infect Dis (1981) 1.83
Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest (1981) 1.82
Phagocytosis and killing of staphylococci by human polymorphonuclear and mononuclear leucocytes. J Clin Pathol (1978) 1.80
Molecular characterization of vancomycin-resistant enterococci from hospitalized patients and poultry products in The Netherlands. J Clin Microbiol (1998) 1.78
Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol (1996) 1.72
Improved detection of methicillin-resistant Staphylococcus aureus using phenyl mannitol broth containing aztreonam and ceftizoxime. J Clin Microbiol (2001) 1.71
Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes. J Clin Microbiol (2000) 1.70
Role of Escherichia coli K capsular antigens during complement activation, C3 fixation, and opsonization. Infect Immun (1979) 1.68
Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis. Yale J Biol Med (1967) 1.67
Extracellular and bacterial factors influencing staphylococcal phagocytosis and killing by human polymorphonuclear leukocytes. Infect Immun (1976) 1.63
Human microglial cell defense against Toxoplasma gondii. The role of cytokines. J Immunol (1994) 1.61
Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis (1996) 1.60
Mechanism of Escherichia coli alpha-hemolysin-induced injury to isolated renal tubular cells. Am J Pathol (1987) 1.57
Dichotomy between opsonization and serum complement activation by encapsulated staphylococci. Infect Immun (1978) 1.56
Quantitation of the third component of human complement attached to the surface of opsonized bacteria: opsonin-deficient sera and phagocytosis-resistant strains. Infect Immun (1979) 1.55
Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med (1993) 1.54
Bacterial rep- mutations that block development of small DNA bacteriophages late in infection. J Virol (1976) 1.53
Penicillin-resistant Streptococcus pneumoniae in the Netherlands: results of a 1-year molecular epidemiologic survey. J Infect Dis (1997) 1.51
Molecular typing of Cryptococcus neoformans: taxonomic and epidemiological aspects. Int J Syst Bacteriol (1997) 1.51
Cognitive slowing and working memory difficulties in chronic fatigue syndrome. Psychosom Med (1997) 1.49
Isolation of protease-proficient, recombinase-deficient recA mutants of Escherichia coli K-12. J Bacteriol (1985) 1.49
Impact of concurrent antimicrobial therapy on catheter-associated urinary tract infection. J Hosp Infect (1991) 1.49
A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc (1991) 1.49
Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus. J Neurovirol (2001) 1.47
Phagocytosis, bacterial killing, and metabolism by purified human lung phagocytes. J Infect Dis (1981) 1.46
Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med (1994) 1.44
Opsonization of four Bacteroides species: role of the classical complement pathway and immunoglobulin. Infect Immun (1980) 1.44
Activated microglia inhibit multiplication of Toxoplasma gondii via a nitric oxide mechanism. Clin Immunol Immunopathol (1993) 1.44
Patient-to-patient spread of a single strain of Corynebacterium striatum causing infections in a surgical intensive care unit. J Clin Microbiol (1996) 1.44
Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int (1991) 1.42
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
Human polymorphonuclear leucocyte receptors for staphylococcal opsonins. Immunology (1977) 1.40
Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol (2000) 1.40
Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine (1991) 1.40
[Gentamicin skin ointment: 200 kilos too much]. Ned Tijdschr Geneeskd (1995) 1.40
[Optimizing antibiotics use policy in the Netherlands. I. The Netherlands Antibiotics Policy Foundation (SWAB)]. Ned Tijdschr Geneeskd (1998) 1.38
Comparative in-vitro activity of meropenem against selected pathogens from hospitalized patients in The Netherlands. MASTIN Study Group. J Antimicrob Chemother (1997) 1.37
[The return of severe infections caused by Streptococcus pyogenes]. Ned Tijdschr Geneeskd (1993) 1.37
Molecular typing of Salmonella typhi strains from Dhaka (Bangladesh) and development of DNA probes identifying plasmid-encoded multidrug-resistant isolates. J Clin Microbiol (1996) 1.37
Complement-mediated phagocytosis of Pseudomonas aeruginosa. J Lab Clin Med (1978) 1.37
Isolation of Chlamydia trachomatis from the lower respiratory tract of adults. Lancet (1980) 1.37
Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids. J Clin Microbiol (1984) 1.36
Phagocytosis by polymorphonuclear leukocytes of Staphylococcus aureus and Pseudomonas aeruginosa adherent to plastic, agar, or glass. J Immunol Methods (1983) 1.36
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst (2000) 1.35
Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis (1983) 1.35
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther (1985) 1.34
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet (1996) 1.34
Cytokine release from microglia: differential inhibition by pentoxifylline and dexamethasone. J Infect Dis (1992) 1.31
Tumor necrosis factor-alpha is a potent ACTH secretagogue: comparison to interleukin-1 beta. Endocrinology (1989) 1.31
Use of pooled urine samples and automated DNA isolation to achieve improved sensitivity and cost-effectiveness of large-scale testing for Chlamydia trachomatis in pregnant women. J Clin Microbiol (2005) 1.31